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Purpose: We conducted a multi-center randomized double-blind study to deter-
mine the effects of 6-month therapy with sulodexide on urinary protein excretion 
in patients with idiopathic Immunoglobulin A (IgA) nephropathy. Materials and 
Methods: A total of seventy-seven patients participated in the study. They were 
randomly allocated to one of three groups: sulodexide 75 mg or 150 mg daily or 
the placebo for 6 months. The primary end point was the achievement, at 6 
months, of at least 50% reduction in urine protein/creatinine ratio (UPCR) from 
the baseline value. Results: At 6 months, the primary end point was achieved by 
12.5% of the patients assigned to the placebo, 4.0% of the patients assigned to su-
lodexide 75 mg daily and 21.4% of those assigned to 150 mg (p=0.308). Treat-
ment with sulodexide 150 mg daily for 6 months significantly reduced log UPCR 
from 6.38±0.77 at baseline to 5.98±0.94 at 6 months (p=0.045), while treatment 
with sulodexide 75 mg daily and placebo did not. Conclusion: A 6-month treat-
ment with sulodexide did not achieve 50% reduction of urinary protein excretion 
in IgA nephropathy patients, but showed a tendency to increase the time-depen-
dent anti-proteinuric effect. Therefore, long-term clinical trials on a larger scale are 
warranted to elucidate the hypothesis that sulodexide affords renal protection in 
IgA nephropathy patients.
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INTRODUCTION
Until recently, there was no effective treatment available for patients with IgA ne-
phropathy. Although there remains no cure regimen, treatment options that slow 
disease progression are becoming available. Since IgA nephropathy may affect up 
to 1.3% of the population,1-4 and in large cohort studies of patients with IgA ne-
phropathy, as many as 30-50% develop end-stage renal disease (ESRD) over a 20-Effect of Sulodexide in IgA Nephropathy
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dang Hospital, and was performed in accordance with the 
Declaration of Helsinki. 
Participants 
Patients of either gender, aged between 18 and 70 years with 
a baseline estimated glomerular filtration rate (eGFR) of 
more than 30 mL/min/1.73 m2 were eligible for the study if 
they had biopsy-proven IgA nephropathy. Patients were re-
quired to have proteinuria, defined as a urinary protein/creat-
inine ratio (UPCR) between 0.1 g/g and 3.5 g/g, and to have 
been receiving treatment with an ACEI or an ARB. The di-
agnosis of IgA nephropathy was based on the histologic as-
sessment of a renal biopsy performed by one investigator 
and was confirmed by immunofluorescence studies showing 
predominant or co-dominant mesangial deposition of 
IgA.7,30 The patients were also required to have stable meta-
bolic control: PCR variation ≤30% from baseline for over 3 
months and blood pressure (BP) ≤160/90 mmHg for at least 
6 months with or without antihypertensive therapy. 
 Exclusion criteria were as follows: neoplasms; severe liver, 
cardiac, or systemic disease; known hypersensitivity to any 
glycosaminoglycans (GAGs); chronic treatment with corti-
costeroids, immunosuppressants or alkylating agents; urinary 
protein excretion rate ≥3.5 g/24 hours; symptomatic urinary 
tract infections; gross hematuria; and pregnancy or lactation.
Sample size
The sample size was estimated according to two indepen-
dent hypotheses; 1) rejection of the hypothesis that P1=P2 
(where P is the number of patients with a 50% reduction in 
UPCR after 6 month of therapy); 2) rejection of the null hy-
pothesis that μ1=μ2=μ3 after 6 months of therapy, only if 
each independent variable accounts for at least 20% of the 
variation, α=0.05 and 1-β is 90%. A 15% withdraw and 
drop-out rate was also added to the calculation. Altogether, 
102 patients were necessary (34 per treatment group). 
Study design
At the study entry (time point 0, T0), a screening assess-
ment was performed for all patients. It included a complete 
medical history, laboratory assessments (blood chemistry, 
blood hematology and urinalysis) and a pregnancy test for 
women with childbearing potential. Patients who met the 
inclusion criteria proceeded to randomization and were ran-
domly assigned, based on a computer-generated random-
ization schedule, to treatment with the placebo, sulodexide 
75 mg or sulodexide 150 mg daily at a 1:1:1 ratio. Patients 
year period after diagnosis,5-7 there is a need for novel ther-
apeutic agents capable of preserving renal function. 
Sulodexide, a mixture of heparan and dermatan sulfate 
(80/20%), targets metabolic defects in the synthesis of the 
matrix and basement membrane as well as in endothelial 
cell dysfunction. It has been shown to reduce proteinuria in 
animal models of diabetic nephropathy.8-11 Several small 
scale clinical studies in humans with diabetic nephropathy 
have demonstrated a consistent trend for the reduction of 
urinary albumin excretion in diabetes mellitus (DM).12-21 
Gambaro, et al.22 reported that the agent achieved its reno-
protective effects primarily through activity on the synthe-
sis of the matrix/glomerular basement membrane (GBM) 
molecules by glomerular cells. Although the complete mech-
anism of sulodexide effects in the kidney has not been fully 
identified, the spectrum of reported effects include the pre-
vention and correction of thickening of the GBM;22,23 restora-
tion of the ionic charge barrier of the GBM;24,25 suppression 
of mesangial cell proliferation;26 reduction of the transform-
ing growth factor-β1 expression and overproduction of col-
lagen; inhibition of heparanase-1;27-29 suppression of pro-
teinuria-induced endothelial cell endothelin production; and 
anti-thrombotic effects. 
The most common alteration associated with IgA ne-
phropathy identified by light microscopy is focal or diffuse 
proliferation of mesangial regions and extracellular matrix 
expansion. Taking into consideration the above alterations 
in IgA nephropathy and the mechanism of sulodexide ef-
fects, we investigated whether sulodexide reduces protein 
excretion rate in patients with idiopathic IgA nephropathy 
who have persistent proteinuria. We have conducted a multi-
center randomized double-blind pilot study in order to de-
termine the effects of a 6-month therapy with sulodexide on 
urinary protein excretion in patients with idiopathic IgA ne-
phropathy who have persistent proteinuria.
MATERIALS AND METHODS
This is a randomized, double-blind, placebo controlled, 
multi-center dose-range finding trial for sulodexide which is 
composed of 80% fast-moving heparan and 20% dermatan 
sulfate (Vessel 2F, Alfa Wassermann SpA, Bologna, Italy). 
All patients gave written informed consent prior to enroll-
ment in the study. The study was approved by the appropri-
ate local research ethics committee at both Seoul National 
University Hospital and Seoul National University Bun-Kitae Bang, et al.
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IgA nephropathy were screened for study. One hundred and 
four patients were randomly assigned with equal allocation 
to treatment with the placebo, a single dose of sulodexide 
75 mg daily, or sulodexide 150 mg daily in two divided 
doses. The profiles of these patients are summarized in Fig.   
1. Of the 104 randomized patients, 77 completed the study. 
Twenty-seven patients discontinued participation due to ad-
verse effects, were lost to follow-up, or spontaneously with-
drew from the study. 
Demographic and clinical baseline characteristics were 
comparable among the three groups. No significant differ-
ence was found between the three groups in terms of age, 
body weight, gender ratio, duration of renal disease, systol-
ic and diastolic blood pressure, dose and frequency of indi-
vidual anti-hypertensive medications, metabolic control, se-
rum creatinine and eGFR (Table 1).
 
Clinical parameters and adverse effects 
Systolic and diastolic blood pressure remained stable through-
out the course of the study and no significant differences 
were observed among the three groups (Table 2). No serious 
adverse events, related or unrelated, to sulodexide was re-
ported. Adverse events leading to withdrawal from the study 
were as follows: rash (two cases), gastrointestinal distur-
bance (four cases), and gross hematuria (one case). There 
was no substantial difference between the groups in the inci-
dence and type of adverse events (Fig. 1). No significant 
changes in mean fibrinogen levels, aPTT, INR, prothrombin 
time and bleeding time were observed between the groups.
 
Evaluation of sulodexide efficacy
The proportion of patients reaching the primary endpoint is 
presented in Table 3. At T6, the primary endpoint was 
achieved in 12.5% of the patients assigned to the placebo, 
4.0% of the patients assigned to sulodexide 75 mg daily 
and 21.4% of the patients assigned to sulodexide 150 mg 
daily. There was no significant difference among the three 
groups in the proportion of patients reaching the primary 
endpoint. The odds ratio for reaching the primary endpoint 
between the sulodexide 150 mg/day group versus the place-
bo group was 1.38 (95% CI 0.65 to 2.94, p=0.40). The odds 
ratio was 0.29 (95% CI 0.03 to 3.02, p=0.30) for the sulo-
dexide 75 mg/day group versus placebo. 
The secondary end point of the study was within-group 
change in log UPCR for 6 months. Treatment with sulodex-
ide 150 mg daily for 6 months significantly reduced logUP-
CR from 6.38±0.77 at T0 to 5.98±0.94 at T6 (p=0.045). 
were instructed to take their medication orally with water 
30 minutes prior to morning and evening meals. A pharma-
ceutist from the ‘Clinical Trials Center’ without any of the 
patients’ information distributed the drugs. Patients visited 
the clinic at 2, 4 and 6 months (T2, T4, and T6, respective-
ly) after randomization. At each follow-up visit, efficacy 
and safety parameters were evaluated and a complete blood 
count, activated partial thromboplastin time (aPTT), fibrin-
ogen, glycosylated hemoglobin (HbA1C), blood chemistry 
(glucose, lipids, urea, creatinine, total protein, albumin, and 
liver functions) were measured. In addition, the first morn-
ing voided urine was collected prior to the day of each fol-
low-up visit for urine protein/creatinine ratio (UPCR). 
 
Study end points
The primary end point was the achievement, at 6 months 
(T6), of at least a 50% reduction in UPCR from the baseline 
value. The secondary end point of the study was within-
group change in log UPCR for 6 months (T6). As the prima-
ry efficacy parameter, we analyzed the proportion of pa-
tients who achieved the primary end point at 6 months (T6).
Statistical analyses
Analyses were performed according to the per protocol 
model on all randomized patients, regardless of adherence 
to treatment. Analysis was also performed from the evalu-
able patients without inclusion of missing values. A log-
transformed value of UPCR was analyzed instead of UPCR 
due to the skewed distribution of the latter value. To evalu-
ate the dose-dependent effect of sulodexide, we compared 
log-transformed UPCR at T0 and T6 in the two sulodexide 
groups with log-transformed UPCR at T0 and T6 in the 
placebo group using Pearson’s chi-square test. Efficacy was 
also evaluated by analyzing within-group change in log-
transformed UPCR for 6 months (T6) using the Wilcoxon 
signed rank test.
Baseline values were compared among the three groups 
using the Kruskal-Wallis test for continuous variables and 
the Pearson’s chi-square test for categorical variables. Sta-
tistical analysis was performed using SPSS version 13.0 for 
Microsoft Windows.
RESULTS
  
Patients profiles and baseline characteristics
Between March 2007 and April 2009, 209 patients with Effect of Sulodexide in IgA Nephropathy
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Table 1. Baseline Characteristics
Parameter
Placebo
(n= 24)
Mean±SD or n (%)
Sulodexide 75 mg/day
(n= 25)
Mean±SD or n (%)
Sulodexide 150 mg/day
(n= 28)
Mean±SD or n (%)
p value
Age (yrs)   42.5±11.6   41.6±13.3   40.4±12.7 NS
Gender, Female 12 (50.0%)    16 (64.0%) 14 (50.0%) NS
Weight (kg)   65.0±11.2   56.9±7.27   61.1±12.6 NS
Duration of IgA nephropathy (months)   73.5±80.5   51.3±62.2   50.6±58.4 NS
Systolic BP (mmHg) 119.0±10.7 118.9±31.4 121.4±19.3 NS
Diastolic BP (mmHg) 71.6±7.7   73.1±19.4 73.6±9.4 NS
Urine P/Cr ratio (Log)   6.38±0.53   6.47±0.79   6.38±0.77 NS
Serum Creatinine (mg/dL)   1.29±0.43   1.27±0.35   1.20±0.26 NS
eGFR (mL/min)   62.8±19.5   57.9±17.7   66.2±12.9 NS
Total cholesterol (mg/dL) 165.2±22.3 175.8±33.1 178.6±28.8 NS
Calcium channel blocker   3 (12.5%)      6 (24.0%)   6 (21.4%) NS
Statin   3 (12.5%)      5 (20.0%)   6 (21.4%) NS
Aspirin 10 (41.7%)    11 (44.0%)   9 (32.1%) NS
ARB 19 (79.2%)    21 (84.0%) 22 (78.6%) NS
ACEI   4 (16.7%)      8 (32.0%)   9 (32.1%) NS
Beta blocker   3 (12.5%)    1 (4.0%)   3 (10.7%) NS
Diuretics   4 (16.7%) 0 (0%)   4 (14.3%) NS
NS, nonsignificant; IgA, Immunoglobulin A; BP, blood pressure; P/Cr, protein creatinine ratio; eGFR,  estimated glomerular filtration ratio; 
ARB, angiotensin II receptor blocker; ACEI, angiotensin converting enzyme inhibitor.
Table 2. Blood Pressure throughout the Study
Treatment group Baseline Week 8 Week 16 Week 24
Systolic blood pressure (mmHg) (mean±SD)
    Placebo 119.0±10.7 119.7±12.8   116.4±13.2 118.6±11.9
    Sulodexide 75 mg/day 118.9±31.4 123.2±13.7 120.7±8.8 121.8±13.7
    Sulodexide 150 mg/day 121.4±12.9 123.4±14.9   119.5±11.3 120.4±13.0
Diastolic blood pressure (mmHg) (mean±SD)
    Placebo 71.6±7.7 72.0±9.9   69.6±9.9   73.0±10.8
    Sulodexide 75 mg/day   73.1±19.4 73.0±9.5   71.6±9.0 73.8±8.6
    Sulodexide 150 mg/day 73.6±9.4 74.3±8.8     71.6±10.2 71.0±9.5
Student’s t test: p>0.05 between three groups at baseline, week 8, 16 and 24, respectively. 
Fig. 1. Patient profiles; the number of patients who were screened for the study, underwent randomization, and completed the study. 
Some patients were excluded for more than one reason. 
Assessed for eligibility (n=209) 
Patients randomized (n=104)
Included in week 24 analysis (n=25)
Allocated to sulodexide 75 mg/day 
(n=34)
Adverse event (n=3)
Refused to continue (n=6)
Other reason (n=0)
Included in week 24 analysis (n=24)
Allocated to placebo 
(n=35)
Adverse event (n=2)
Refused to continue (n=5)
Other reason (n=4)
Included in week 24 analysis (n=28)
Allocated to sulodexide 150 mg/day 
(n=35)
Adverse event (n=2)
Refused to continue (n=4)
Other reason (n=1)
Excluded (n=105)Kitae Bang, et al.
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Sulodexide apparently alters glomerular permeability and 
effectively reduces proteinuria by a non-blood pressure, non-
renin angiotensin aldosterone system (RAAS) related mech-
anism. As a result, sulodexide could add to the therapeutic 
options for IgA nephropathy patients who fail to respond to 
RAAS inhibition. Moreover, it may further reduce protein-
uria in patients who show a partial response to RAAS inhi-
bition. Such additive effects are very important. 
Sulodexide is a preparation of low-molecular weight por-
cine GAG polysaccharides comprised of fast-moving hepa-
rin (80%), and dermatan sulfate (20%) with a mean molec-
ular weight of 11,000-15,000 Da. The drug is absorbed 
orally8,31 and although it was first evaluated as an anti-throm-
botic drug, it has no anticoagulant effect after oral adminis-
tration.32 The drug has been shown to improve blood flow 
by lowering viscosity,33,34 to reduce the occurrence of car-
However, treatment with sulodexide 75 mg daily and the 
placebo did not show a significant reduction in logUPCR 
(75 mg group, logUPCR from 6.47±0.79 at T0 to 6.63±0.74 
at T6, p=0.487; placebo group, logUPCR from 6.38±0.53 
at T0 to 6.29±0.70 at T6, p=0.190) (Table 4). By the end of 
the study period, treatment with sulodexide 150 mg daily 
for 6 months had reduced the geometric mean in UPCR by 
33%, as compared to the baseline (p=0.045) and showed a 
tendency to increase the time-dependent anti-proteinuric ef-
fect (Fig. 2). There were no significant differences between 
either of the sulodexide groups and the placebo group in the 
change in the logUPCR to any of the follow-up time points 
(Table 4, Fig. 2). 
DISCUSSION
We investigated whether sulodexide is able to reduce the 
protein excretion rate in patients with idiopathic IgA ne-
phropathy who have persistent proteinuria despite treatment 
with an ACEI or an ARB. This pilot study was the first to 
evaluate the efficacy of sulodexide in biopsy-proven IgA ne-
phropathy patients. Many previous studies have shown the 
efficacy of sulodexide in diabetic nephropathy. However, a 
6-month treatment with sulodexide did not achieve a 50% re-
duction of urinary protein excretion in IgA nephropathy pa-
tients. Yet the study results indicated a tendency to increase 
the time-dependent anti-proteinuric effect in the sulodexide 
150 mg/day group. Although our findings were incongruent 
with those previously reported from small explorative inves-
tigations with diabetic nephropathy patients, we found that 
long-term treatment with a high dose of sulodexide might re-
duce urinary protein excretion in IgA nephropathy patients. 
Table 3. Patients Achieving >50% Reduction of Proteinuria at 6 months, n and (%)
Placebo Sulodexide 75 mg/day Sulodexide 150 mg/day
Number of patients available   
  for analysis at 6 months
24 25 28
Patients with >50% reduction  
  of proteinuria at 6 months
3 (12.5%) 1 (4.0%) 6 (21.4%)
p=0.308  
Table 4. Effect of Sulodexide on Urine Protein/Creatinine Ratio in the Whole Study Group (Log scale)
Treatment group Baseline Week 8 Week 16 Week 24
Placebo 6.38±0.53 6.28±0.58 6.31±0.83 6.29±0.70
Sulodexide 75 mg/day 6.47±0.79 6.34±0.80 6.47±0.83 6.63±0.74
Sulodexide 150 mg/day   6.38±0.77* 6.00±0.71 6.12±0.89   5.98±0.94*
*p=0.045 between baseline and week 24 in Sulodexide 150 mg/day group (p=0.190 at week 8 and p=0.487 at week 16 in Sulodexide 
150 mg/day group)
Fig. 2. Changes from baseline in urinary protein-to-creatinine ratio (UPCR) 
according to study group. The change from the baseline, in the geometric 
mean, with 95% confidence intervals, is shown for UPCR.
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cals. Institutional Review Board(IRB)/Ethics Committee 
approval was obtained.
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Studies of proteoglycan sulfate incorporation have im-
plied that diminished GAG content is, at least, the result of a 
diminished rate of biosynthesis of heparan sulfate proteogly-
can.38,39 A simple explanation of the efficacy of sulodexide 
and related compounds is that they restore the anionic hepa-
rin sulfate charges on the glomerular basement membrane. 
Transforming growth factor-β1 (TGF-β1) has emerged as a 
predominant fibrogenic cytokine, which leads to glomeru-
losclerosis, interstitial fibrosis, and tubular atrophy in IgA 
nephropathy. Renal localization of TGF-β1 correlates with 
the severity of tubulointerstitial damage in patients with 
IgA nephropathy.40 Therefore, the beneficial effects of GAGs 
are partially related to downregulation of TGF-β expres-
sion.8 Inhibition of heparanase-1 has been proposed as a 
further nephroprotective mechanism of GAGs.27 Heparan-
ase-1 is an endo-β(1-4)-D-glucuronidase that cleaves the 
glycosidic bond within the heparin sulfate chain. The GAG 
sulodexide has been shown to be an inhibitor of hepa-
ranse-1, whose activity is tightly regulated to ensure the 
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well-controlled BP and already receiving ACEI or ARB ther-
apy was noteworthy. 
Our preliminary study suggests that sulodexide had an 
additional anti-proteinuric effect for biopsy-proven IgA ne-
phropathy patients who had already been treated with RAS 
inhibition. Larger-scale clinical trials including a total of 
over 204 patients are warranted to obtain greater certainty 
of the anti-proteinuric effects of sulodexide for IgA ne-
phropathy. 
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